REGN:NSD-Regeneron Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 756.81

Change

0.00 (0.00)%

Market Cap

USD 92.70B

Volume

1.37M

Analyst Target

USD 674.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 121.60B
ARGX argenx NV ADR

N/A

USD 35.89B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 30.38B
BGNE BeiGene Ltd

N/A

USD 22.85B
MRNA Moderna Inc

N/A

USD 21.00B
UTHR United Therapeutics Corporatio..

N/A

USD 16.70B
RPRX Royalty Pharma Plc

N/A

USD 15.14B
INCY Incyte Corporation

N/A

USD 14.67B
SMMT Summit Therapeutics PLC

N/A

USD 13.75B
PCVX Vaxcyte Inc

N/A

USD 13.28B

ETFs Containing REGN

EMEH:SW BNP Paribas Easy Energy &.. 8.55 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 8.30 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 8.28 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 6.88 % 0.35 %

N/A

USD 0.43B
CURG:LSE VanEck Genomics and Healt.. 5.62 % 0.00 %

N/A

USD 4.80M
SPQH:XETRA Global X S&P 500® Quarte.. 4.95 % 0.00 %

N/A

USD 0.04B
ZWHC:CA BMO Covered Call Health C.. 4.73 % 0.00 %

N/A

N/A
UBIO 4.54 % 0.95 %

N/A

N/A
EGUSAS:SW UBS (Irl) Fund Solutions .. 4.35 % 0.00 %

N/A

USD 0.10B
MEDX Horizon Kinetics Medical .. 4.26 % 0.00 %

N/A

N/A
PINK Simplify Exchange Traded .. 4.19 % 0.00 %

N/A

USD 0.18B
XGSD:SW Xtrackers Stoxx Global Se.. 4.17 % 0.00 %

N/A

USD 0.68B
XGSD:XETRA Xtrackers Stoxx Global Se.. 4.17 % 0.00 %

N/A

N/A
XDNA:CA iShares Genomics Immunolo.. 4.15 % 0.00 %

N/A

CAD 5.26M
BIS ProShares UltraShort Nasd.. 4.13 % 0.95 %

N/A

USD 3.55M
HEAL:CA 3.97 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 3.94 % 0.95 %

N/A

USD 0.07B
FDG American Century ETF Trus.. 3.60 % 0.00 %

N/A

N/A
CAPS:LSE First Trust Capital Stren.. 2.26 % 0.00 %

N/A

N/A
XLVE:CA Mulvihill U.S. Health Car.. 1.84 % 0.00 %

N/A

N/A
ACWV 0.00 % 0.20 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
FPX First Trust US Equity Opp.. 0.00 % 0.59 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 6.55B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

N/A

USD 0.08B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

N/A
PXLG Invesco S&P 500 GARP ETF 0.00 % 0.39 %

N/A

N/A
IDNA iShares Genomics Immunolo.. 0.00 % 0.00 %

N/A

USD 0.15B
HERS-B:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
XMW:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

N/A

CAD 0.18B
XMY:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

N/A

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

N/A

N/A
HERS:CA 0.00 % 0.62 %

N/A

N/A
FPX:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
FPXU:PA First Trust US Equity Opp.. 0.00 % 0.00 %

N/A

USD 6.23M
SMRT:PA 0.00 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
EMEH:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

N/A

N/A
GSDE:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

N/A

N/A
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
SM8T:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.04B
BIOT 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
DWEQ 0.00 % 0.00 %

N/A

N/A
LYFE 0.00 % 0.00 %

N/A

N/A
SMRU:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 3.61M
PFUT Putnam Sustainable Future.. 0.00 % 0.00 %

N/A

USD 0.31B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.92% 57% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.92% 57% F 36% F
Trailing 12 Months  
Capital Gain -5.69% 55% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.69% 55% F 36% F
Trailing 5 Years  
Capital Gain 119.71% 85% B 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 119.71% 85% B 85% B
Average Annual (5 Year Horizon)  
Capital Gain 18.84% 63% D 72% C
Dividend Return 18.84% 63% D 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 16.03% 98% N/A 82% B
Risk Adjusted Return 117.56% 100% F 98% N/A
Market Capitalization 92.70B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.